Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Legend Biotech Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Legend Biotech şirketinin kazançları yıllık ortalama -18.4% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.7% oranında artan oldu. Gelirler yıllık ortalama 60.1% oranında artan oldu.

Anahtar bilgiler

-18.4%

Kazanç büyüme oranı

-6.7%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	60.1%
Özkaynak getirisi	-24.6%
Net Marj	-62.5%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion

Sep 18

Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Aug 01

Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges

Jul 30

Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Jul 05

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

May 14

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

May 13

An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Dec 14

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Sep 27

Legend Biotech stock slides on proposed ADS offering

Jul 25

Legend Biotech ends Phase 1 trial for lymphoma candidate

Jul 07

News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts

Jun 05

Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?

May 14

Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Mar 22

Legend Biotech: Carvykti Approval Makes For A Buy Opportunity

Mar 04

Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be

Mar 03

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Dec 30

Gelir ve Gider Dağılımı

Legend Biotech nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:LEGN Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	456	-285	233	0
31 Mar 24	343	-466	217	0
31 Dec 23	285	-518	201	0
30 Sep 23	233	-509	191	0
30 Jun 23	165	-532	184	0
31 Mar 23	112	-517	180	0
31 Dec 22	117	-446	174	0
30 Sep 22	106	-416	192	-227
30 Jun 22	96	-457	181	-155
31 Mar 22	119	-346	161	313
31 Dec 21	69	-404	150	0
30 Sep 21	93	-356	113	294
30 Jun 21	89	-297	97	285
31 Mar 21	80	-340	85	184
31 Dec 20	75	-266	73	0
30 Sep 20	59	-310	55	231
30 Jun 20	64	-271	46	210
31 Mar 20	61	-165	38	189
01 Jan 20	62	-102	32	162
31 Dec 18	49	-3	4	61
31 Dec 17	24	9	2	8

Kaliteli Kazançlar: LEGN şu anda kârlı değil.

Büyüyen Kar Marjı: LEGN şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: LEGN kârlı değildir ve zararlar son 5 yılda yılda 18.4% oranında artmıştır.

Büyüme Hızlandırma: LEGN 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: LEGN kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 0.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: LEGN hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -24.59% ) sahiptir.

Legend Biotech Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

Consensus EPS estimates fall by 14%, revenue upgraded

Legend Biotech Corporation, Annual General Meeting, Oct 21, 2024

Chief Financial Officer notifies of intention to sell stock

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion

Legend Biotech Achieves Breakthrough with Cilta-Cel Approval in China, Offering New Hope for Multiple Myeloma Patients

Consensus estimates of losses per share improve by 33%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Legend Biotech Corporation Appoints Peter Salovey as Independent Director, Effective August 9, 2024

Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges

Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Legend Biotech Corporation Announces Positive Overall Survival Results of Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

CEO & Director notifies of intention to sell stock

Legend Biotech Corporation Shares Data on the Earlier Use to Date of CARVYKTI in the Treatment of Multiple Myeloma and Important Subgroup Analyses At ASCO and EHA

Legend Biotech Corporation to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Legend Biotech Corporation Announces CARVYKTI (Ciltacabtagene Autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

CEO & Director notifies of intention to sell stock

Legend Biotech: Solid Traction With Carvykti Rollout

Legend Biotech Provides Update on U.S. FDA and EMA Applications for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel) in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Legend Biotech Announces U.S. FDA Label Update for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel)

Legend Biotech Corporation Announces Patient-Reported Outcome (Pro) Data from the Phase 3 CARTITUDE-4 Study

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Legend Biotech Corporation, Annual General Meeting, Sep 21, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 11%

Legend Biotech Corporation Announces Submission of Supplemental Application to U.S. FDA for Expanded Use of CARVYKTI® (Ciltacabtagene Autoleucel)

Legend Biotech Corporation Announces Results from the Phase 3 CARTITUDE-4 Study

CEO & Director notifies of intention to sell stock

Legend Biotech Corporation Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI®? (Ciltacabtagene Autoleucel)

Price target increased by 7.7% to US$79.70

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Legend Biotech Corporation to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350 million.

Chief Financial Officer notifies of intention to sell stock

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Independent Director notifies of intention to sell stock

Full year 2022 earnings: Revenues miss analyst expectations

Second quarter 2022 earnings released: US$1.25 loss per share (vs US$0.66 loss in 2Q 2021)

Legend Biotech Corporation Announces Research and Development Update

Legend Biotech Receives Notification of Delinquency from The Nasdaq Stock Market LLC

Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Chief Financial Officer notifies of intention to sell stock

Legend Biotech Corporation Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer

High number of new and inexperienced directors

Legend Biotech Corporation Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022

Legend Biotech Corporation Elects Philip Yau as Director

Consensus forecasts updated

Legend Biotech Corporation Announces that CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Legend Biotech Corporation, Annual General Meeting, Oct 14, 2022

Legend Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Legend Biotech Corporation Announces Board Changes

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million.

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million.

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Legend Biotech stock slides on proposed ADS offering